Northern Trust Corp Icosavax, Inc. Transaction History

Northern Trust Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$5.95 - $15.79 $64,878 - $172,174	10,904 Added 4.01%	282,513 $4.45 Million
Q3 2023 Nov 13, 2023	BUY	$7.22 - $10.05 $207,112 - $288,294	28,686 Added 11.81%	271,609 $2.1 Million
Q2 2023 Aug 11, 2023	BUY	$4.89 - $10.57 $345,512 - $746,844	70,657 Added 41.02%	242,923 $2.41 Million
Q1 2023 May 15, 2023	SELL	$5.62 - $11.51 $46,466 - $95,164	-8,268 Reduced 4.58%	172,266 $999,000
Q4 2022 Feb 13, 2023	BUY	$2.32 - $10.97 $32,746 - $154,841	14,115 Added 8.48%	180,534 $1.43 Million
Q3 2022 Nov 14, 2022	SELL	$3.09 - $9.21 $5,602 - $16,697	-1,813 Reduced 1.08%	166,419 $526,000
Q2 2022 Aug 12, 2022	SELL	$5.7 - $10.33 $116,964 - $211,971	-20,520 Reduced 10.87%	168,232 $964,000
Q1 2022 May 13, 2022	BUY	$4.41 - $22.5 $299,716 - $1.53 Million	67,963 Added 56.27%	188,752 $1.33 Million
Q4 2021 Feb 08, 2022	BUY	$21.07 - $34.98 $54,887 - $91,122	2,605 Added 2.2%	120,789 $2.76 Million
Q3 2021 Nov 15, 2021	BUY	$24.85 - $40.25 $2.94 Million - $4.76 Million	118,184 New	118,184 $3.5 Million

1.37M

Ticker ICVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,885,200
Description
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.